Show simple item record

dc.contributor.author Veres, Gábor
dc.contributor.author Szabó, Dolóresz
dc.contributor.author Herczegné Várkonyi, Ágnes
dc.contributor.author Tari B
dc.contributor.author Polgar M
dc.contributor.author B Kovacs J
dc.contributor.author Horvath A
dc.contributor.author Tomsits, Erika
dc.contributor.author Tokodi I
dc.contributor.author Bodánszky, Hedvig
dc.contributor.author Dezsőfi, Antal
dc.contributor.author Szakos E
dc.contributor.author Vass, Noémi
dc.contributor.author Ruszinko V
dc.contributor.author Kovács, Márta
dc.contributor.author Müller, Katalin Eszter
dc.contributor.author Arató, András
dc.date.accessioned 2017-05-31T13:03:43Z
dc.date.available 2017-05-31T13:03:43Z
dc.date.issued 2010
dc.identifier 76249118851
dc.identifier.citation pagination=179-183; journalVolume=151; journalIssueNumber=5; journalTitle=ORVOSI HETILAP;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/4199
dc.identifier.uri doi:10.1556/OH.2010.28792
dc.description.abstract Infliximab, the chimeric antibody to tumor necrosis factor-alpha, is indicated for medically refractory pediatric Crohn disease. Aim of our study was to examine the efficacy and side effects of infliximab therapy in Hungarian pediatric patients with Crohn disease since the authorisation of medicine for children to 31.12.2008. 23 children with refractory Crohn disease received infliximab during this period. Induction therapy with 5 mg/kg infliximab at weeks 0, 2, and 6 was introduced. 18 patients (81.8%) achieved clinical response, and 13 patients (59.1%) were in remission at the 6th week of the observation period. The evaluation was based on data of 22 children. Fistula closure rate was 70% at the at the 6th week. Two patients had acute infusion reaction, one had severe anaphilactic reaction after infliximab infusion. Chronic side effects were also observed in three cases. In our study infliximab induction therapy was effective in most pediatric patients with therapy refractory Crohn disease.
dc.relation.ispartof urn:issn:0030-6002
dc.title Crohn-beteg gyermekek infliximabkezelésének kezdeti tapasztalatai hazánkban [Analysis of infliximab treated pediatric patients with Crohn disease in Hungary]
dc.type Journal Article
dc.date.updated 2017-03-30T13:04:24Z
dc.language.rfc3066 hu
dc.identifier.mtmt 1485824
dc.identifier.pubmed 20083466
dc.contributor.department SE/AOK/K/I. Sz. Gyermekgyógyászati Klinika
dc.contributor.department SE/AOK/K/II. Sz. Gyermekgyógyászati Klinika
dc.contributor.department SZTE/ÁOK/Gyermekgyógyászati Klinika és Gyermek Egészségügyi Központ
dc.contributor.institution Semmelweis Egyetem
dc.contributor.institution Szegedi Tudományegyetem
dc.mtmt.swordnote Multicentrikus tanulmány


Files in this item

This file is available only from Semmelweis network

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account